Laidlaw Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Laidlaw Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-104,841	Closed	-$264K	–	409
2021 Q3	$264K	Sell	104,841 -18,889	-15%	-$48.5K	0.07%	198
2021 Q2	$353K	Buy	123,730 +8,000	+7%	+$20.7K	0.09%	182
2021 Q1	$272K	Sell	115,730 -54,928	-32%	-$132K	0.09%	174
2020 Q4	$300K	Buy	170,658 +37,990	+29%	+$53.1K	0.06%	265
2020 Q3	$124K	Buy	132,668 +13,039	+11%	+$11.5K	0.06%	200
2020 Q2	$104K	Buy	119,629 +12,250	+11%	+$10.8K	0.05%	175
2020 Q1	$89K	Buy	107,379 +77,526	+260%	+$77.2K	0.06%	145
2019 Q4	$27K	Buy	+29,853	New	+$24.9K	0.02%	168

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Laidlaw Wealth Management's LCTX Position: Q4 2021 in Review

Laidlaw Wealth Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2021, closing a stake of 104,841 shares — an estimated $264K sold.

Laidlaw Wealth Management first reported a position in LCTX in Q4 2019 and held it in 8 quarters. The position peaked at $353K in Q2 2021. 124 funds tracked by Wall St. Rank hold LCTX as of Q4 2021.

Laidlaw Wealth Management reported no remaining Lineage Cell Therapeutics position as of Q4 2021 after selling out during the quarter.
Laidlaw Wealth Management sold 104,841 Lineage Cell Therapeutics shares in Q4 2021, an estimated $264K.
Laidlaw Wealth Management first reported a position in Lineage Cell Therapeutics in Q4 2019 and held it in 8 quarters.
Laidlaw Wealth Management's Lineage Cell Therapeutics position peaked at $353K in Q2 2021.
124 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2021.

Based on Laidlaw Wealth Management's 13F filing for Q4 2021, filed 14 Feb 2022.